Eiger BioPharmaceuticals, Inc. (EIGR) Financials
EIGR Assets vs Liabilities
Date | Assets | Liabilities |
---|---|---|
2023-09-30 | 55.7 million | 57.3 million |
2023-06-30 | 72.4 million | 57.1 million |
2023-03-31 | 99.2 million | 64.0 million |
2022-12-31 | 120.1 million | 64.8 million |
EIGR Free Cash Flow and Stock based compensation
Graph available only for supporters. Become a supporter to see it.
Date | Free Cash Flow | Stock based compensation |
---|---|---|
2023-09-30 | -14.6 million | 1.0 million |
2023-06-30 | -22.1 million | 745000 |
2023-03-31 | -24.2 million | 2.5 million |
2022-12-31 | -22.5 million | 1.8 million |
EIGR Net Income
No data available :(
EIGR Cash and Debt
Graph available only for supporters. Become a supporter to see it.
Date | Cash | Debt | Capital Lease |
---|---|---|---|
2023-09-30 | 39.4 million | - | 205000 |
2023-06-30 | 53.6 million | 40.3 million | 322000 |
2023-03-31 | 75.3 million | 40.0 million | 436000 |
2022-12-31 | 98.9 million | 39.6 million | 574000 |
EIGR Shares Outstanding
EIGR Expenses
Graph available only for supporters. Become a supporter to see it.
Date | Capex | R&D | G&A | S&M |
---|---|---|---|---|
2023-09-30 | - | 14.6 million | 5.5 million | - |
2023-06-30 | 17000 | 19.4 million | 5.5 million | - |
2023-03-31 | 216000 | 16.7 million | 9.5 million | - |
2022-12-31 | 224000 | 18.5 million | 8.3 million | - |
EIGR Cost of Revenue
Graph available only for supporters. Become a supporter to see it.
Date | Revenue | Cost of Revenue |
---|---|---|
2023-09-30 | 3.2 million | 115000 |
2023-06-30 | 4.6 million | 310000 |
2023-03-31 | 4.1 million | 118000 |
2022-12-31 | 2.7 million | 345000 |
EIGR
Price: $1.72
52 week price:
Earnings Per Share: -58.50 USD
P/E Ratio: -0.10
Exchange: NGM
Sector: Healthcare
Industry: Biotechnology
Volume: 759300
Ebitda: -8.8 millionMarket Capitalization: 2.6 million